Sensing No Room For Price Compromise, Janssen Pulls Invokana From Germany
This article was originally published in The Pink Sheet Daily
Executive Summary
After a disappointing assessment from Germany’s two reimbursement bodies, Janssen has opted to withdraw it diabetes drug, believing it cannot secure a competitive price.